Clinical trial

Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

NCT00474539 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed

Key facts

NCT number NCT00474539
Title Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
Official title A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain
Lead sponsor Wyeth is now a wholly owned subsidiary of Pfizer, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Vaccines, Pneumococcal
Intervention type Biological
Interventions 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
Enrollment 449
Start date Jul 1, 2007
Primary completion Mar 1, 2009
Completion Mar 1, 2009
First posted May 17, 2007
Last update posted Mar 5, 2013
Countries Spain

At a glance

  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies